Answers are grounded in this paper and cite their sources.
Randomized trial reveals mepolizumab increases remission and lowers steroid use in eosinophilic granulomatosis with polyangiitis, suggesting targeted therapy benefits despite partial response.
In participants with eosinophilic granulomatosis with polyangiitis, mepolizumab resulted in significantly more weeks in remission and a higher proportion of participants in remission than did placebo, thus allowing for reduced glucocorticoid use. Even so, only approximately half the participants treated with mepolizumab had protocol-defined remission. (Funded by GlaxoSmithKline and the National Institute of Allergy and Infectious Diseases; ClinicalTrials.gov number, NCT02020889 .).
No takes yet. Share an insight, caveat, or question.
Wechsler et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: